A Phase II of Nivolumab Plus Ipilimumab in Non-resectable Sarcoma and Endometrial Carcinoma
Status:
Unknown status
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether nivolumab plus ipilimumab are effective and
safe in the treatment of sarcoma and endometrial carcinoma patients with somatic deficient
MMR as a selection tool.